Home » Whole-Genome Sequencing Could Complement GWAS to Find Rare Variants Associated with Disease Risk

Whole-Genome Sequencing Could Complement GWAS to Find Rare Variants Associated with Disease Risk

Mar 08, 2011
Premium

By Monica Heger

Whole-genome sequencing in combination with genome-wide association studies could be the key to uncovering rare variants associated with disease risk, according to researchers from Decode Genetics.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Related Articles

May 09, 2014

NextCode Seeks to Build Business on Proprietary Informatics Infrastructure from DeCode

Premium
Jul 21, 2014

Sequencing Uncovers Rare Variants Linked to Noonan Syndrome, Aids in Diagnosis

Jan 19, 2015

Young Investigator Profile: Gina Peloso

Jun 19, 2014

Genomics in the Journals

Apr 03, 2014

Rare Variants Linked to Congenital Heart Defects in Humans

Apr 29, 2014

Exome Sequencing Study Identifies Chromatin Remodeling-related Mutations in Schizophrenia

The Scan

This Week in PLOS

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

Things Not Found

With a new collection, PLOS highlights negative results it has published.

Is the Sequencer Half Full or Half Empty?

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

Packs a Punch

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.

What's Popular?

In Clinical Sequencing

  1. AGBT: WashU Applies Genomic Testing to Predict Cancer Relapse, Drug Response, Vaccine Epitopes

    Premium

  2. U of Cambridge, Genomics England, Illumina to Sequence 10,000 Genomes from Rare Disease Patients

  3. Personal Genome Diagnostics, Blueprint Medicines to ID Novel Drug Targets in Cancer

  4. Personal Genome Diagnostics Aims for FDA Clearance of NGS-based Cancer Products

    Premium

  5. Q&A: Matt Posard on Illumina's Clinically Focused Business Unit

    Premium

Sponsorships

Privacy Policy.  Copyright © 2015 Genomeweb LLC.  All Rights Reserved.